Abogen

Executive Summary

Abogen Biosciences is a clinical-stage biotechnology company based in Suzhou, China, pioneering mRNA-based therapeutics and vaccines. Founded in 2019, the company has developed a fully integrated mRNA-LNP platform that leverages AI-driven sequence design and lipid nanoparticle delivery, with capabilities spanning from discovery to commercial-scale manufacturing. Abogen's pipeline focuses on oncology, infectious diseases, and autoimmune disorders, positioning it as a key player in the rapidly evolving mRNA therapeutics space. Although still in Phase I clinical trials, the company has demonstrated robust platform versatility and has attracted significant attention from investors and partners due to its potential to address unmet medical needs. With a strong emphasis on innovation and scalability, Abogen is well-positioned to capitalize on the growing demand for mRNA-based solutions beyond COVID-19 vaccines.

Upcoming Catalysts (preview)

• Q3 2026Phase I/II data readout for lead oncology candidate (mRNA cancer vaccine)65% success
• Q4 2026Strategic partnership or licensing deal for infectious disease mRNA vaccine50% success
• Q2 2026Completion of commercial-scale manufacturing facility expansion85% success